Johnson & Johnson

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade Johnson & Johnson 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About JNJ

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. 

CEO
Joaquin Duato
CEOJoaquin Duato
Employees
139,800
Employees139,800
Headquarters
New Brunswick, New Jersey
HeadquartersNew Brunswick, New Jersey
Founded
1887
Founded1887
Employees
139,800
Employees139,800

JNJ Key Statistics

Market cap
526.85B
Market cap526.85B
Price-Earnings ratio
21.19
Price-Earnings ratio21.19
Dividend yield
2.34%
Dividend yield2.34%
Average volume
9.14M
Average volume9.14M
High today
$220.11
High today$220.11
Low today
$217.49
Low today$217.49
Open price
$219.20
Open price$219.20
Volume
10.02M
Volume10.02M
52 Week high
$220.11
52 Week high$220.11
52 Week low
$141.50
52 Week low$141.50

Stock Snapshot

As of today, Johnson & Johnson(JNJ) shares are valued at $218.75. The company's market cap stands at 526.85B, with a P/E ratio of 21.19 and a dividend yield of 2.3%.

On 2026-01-17, Johnson & Johnson(JNJ) stock traded between a low of $217.49 and a high of $220.11. Shares are currently priced at $218.75, which is +0.6% above the low and -0.6% below the high.

Johnson & Johnson(JNJ) shares are trading with a volume of 10.02M, against a daily average of 9.14M.

During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $220.11 at its peak.

During the past year, Johnson & Johnson(JNJ) stock moved between $141.50 at its lowest and $220.11 at its peak.

JNJ News

Nasdaq 1d
June 2027 Options Now Available For Johnson & Johnson

Investors in Johnson & Johnson (Symbol: JNJ) saw new options begin trading today, for the June 2027 expiration. One of the key inputs that goes into the price a...

June 2027 Options Now Available For Johnson & Johnson
Simply Wall St 2d
Assessing ORIC Pharmaceuticals Valuation After Fresh Buy Ratings And Johnson & Johnson Collaboration

ORIC Pharmaceuticals (ORIC) stock has been in focus after fresh buy ratings from several research firms coincided with encouraging trial updates for its lead on...

Assessing ORIC Pharmaceuticals Valuation After Fresh Buy Ratings And Johnson & Johnson Collaboration
Simply Wall St 2d
Johnson & Johnson Is Up 5.3% After New TECVAYLI Phase 3 Myeloma Data - Has The Bull Case Changed?

Johnson & Johnson recently reported positive topline Phase 3 MajesTEC-9 results showing TECVAYLI monotherapy improved progression-free and overall survival vers...

Johnson & Johnson Is Up 5.3% After New TECVAYLI Phase 3 Myeloma Data - Has The Bull Case Changed?

Analyst ratings

56%

of 27 ratings
Buy
55.6%
Hold
37%
Sell
7.4%

More JNJ News

Benzinga 2d
Johnson & Johnson Drug Slows Blood Cancer, Extends Survival In Pretreated Patients

Johnson & Johnson (NYSE:JNJ) shared topline results from the investigational Phase 3 MajesTEC-9 study of Tecvayli (teclistamab-cqyv) monotherapy for multiple my...

Johnson & Johnson Drug Slows Blood Cancer, Extends Survival In Pretreated Patients
Nasdaq 3d
Johnson & Johnson Reaches Analyst Target Price

In recent trading, shares of Johnson & Johnson (Symbol: JNJ) have crossed above the average analyst 12-month target price of $213.83, changing hands for $218.61...

Johnson & Johnson Reaches Analyst Target Price
TipRanks 3d
Johnson & Johnson’s tecvayli shows efficacy in Phase 3 multiple myeloma study

Johnson & Johnson announced positive topline results from the investigational Phase 3 MajesTEC-9 study of tecvayli – teclistamab-cqyv – monotherapy, showing a 7...

Simply Wall St 3d
Is Johnson & Johnson Still Fairly Priced After Its Strong 12-Month Rally?

If you are wondering whether Johnson & Johnson is still reasonably priced after its recent run, this article will walk through what the current share price migh...

Is Johnson & Johnson Still Fairly Priced After Its Strong 12-Month Rally?
TipRanks 4d
Clarity Medical Group Maintains Market Lead as It Works Toward Trading Resumption

Claim 70% Off TipRanks Premium An announcement from Clarity Medical Group Holding Limited ( (HK:1406) ) is now available. Clarity Medical Group Holding Limite...

Benzinga 4d
Court Orders Recalculation Of Damages In Johnson & Johnson Auris Case

Johnson & Johnson (NYSE:JNJ) on Monday reportedly secured a partial legal victory after Delaware's highest court overturned a portion of a $1 billion damages aw...

Court Orders Recalculation Of Damages In Johnson & Johnson Auris Case
Nasdaq 5d
What's Powering J&J's MedTech Growth Ahead of Q4 Release?

Johnson & Johnson's JNJ medical devices segment, known as MedTech, offers products in the orthopedics, surgery, cardiovascular and vision markets. The MedTech s...

What's Powering J&J's MedTech Growth Ahead of Q4 Release?

People also own

Based on the portfolios of people who own JNJ. This list is generated using Robinhood data, and it’s not a recommendation.
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the .